2019
Cost‐effectiveness of expanding the capacity of opioid agonist treatment in Ukraine: dynamic modeling analysis
Morozova O, Crawford FW, Cohen T, Paltiel AD, Altice FL. Cost‐effectiveness of expanding the capacity of opioid agonist treatment in Ukraine: dynamic modeling analysis. Addiction 2019, 115: 437-450. PMID: 31478285, PMCID: PMC7015766, DOI: 10.1111/add.14797.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentOpioid use disorderOAT coverageAgonist treatmentGross domestic productOpioid use initiationOpioid addiction epidemicOAT accessHIV epidemicUse disordersAddiction epidemicCapita gross domestic productPay thresholdsTreatment demandUse initiationAddiction treatmentIncremental costBaseline capacityTreatmentPotential peer effectsDomestic productTreatment spilloversEpidemicPeer effectsCoverage levels
2018
Prospects for Tuberculosis Elimination in the United States: Results of a Transmission Dynamic Model
Menzies NA, Cohen T, Hill AN, Yaesoubi R, Galer K, Wolf E, Marks SM, Salomon JA. Prospects for Tuberculosis Elimination in the United States: Results of a Transmission Dynamic Model. American Journal Of Epidemiology 2018, 187: 2011-2020. PMID: 29762657, PMCID: PMC6119121, DOI: 10.1093/aje/kwy094.Peer-Reviewed Original ResearchConceptsTB preventionTB eliminationLatent TB infection (LTBI) screeningTB case detectionHigh-risk populationImportant health benefitsTransmission dynamic modelIncident TBActive TBTuberculosis eliminationInfection testingTB controlTB incidenceEpidemiologic evidenceTB transmissionInfection screeningCase detectionTuberculosis trendsUS populationRisk determinantsHealth benefitsTreatment qualityUnited StatesTreatment activitiesTreatment
2017
Catastrophic costs potentially averted by tuberculosis control in India and South Africa: a modelling study
Verguet S, Riumallo-Herl C, Gomez GB, Menzies NA, Houben RMGJ, Sumner T, Lalli M, White RG, Salomon JA, Cohen T, Foster N, Chatterjee S, Sweeney S, Baena IG, Lönnroth K, Weil DE, Vassall A. Catastrophic costs potentially averted by tuberculosis control in India and South Africa: a modelling study. The Lancet Global Health 2017, 5: e1123-e1132. PMID: 29025634, PMCID: PMC5640802, DOI: 10.1016/s2214-109x(17)30341-8.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisEnd TB StrategyTuberculosis servicesCatastrophic costsTB StrategyDrug-sensitive tuberculosisCatastrophic financial burdenAnnual household incomeTuberculosis careTuberculosis controlEconomic burdenTuberculosisIntervention effectsMelinda Gates FoundationHousehold incomeIndirect costsFinancial burdenExpansion of accessPatientsTotal annual household incomeTreatmentCareGates FoundationBurdenIntervention scenarios
2016
Within-Host Heterogeneity of Mycobacterium tuberculosis Infection Is Associated With Poor Early Treatment Response: A Prospective Cohort Study
Cohen T, Chindelevitch L, Misra R, Kempner ME, Galea J, Moodley P, Wilson D. Within-Host Heterogeneity of Mycobacterium tuberculosis Infection Is Associated With Poor Early Treatment Response: A Prospective Cohort Study. The Journal Of Infectious Diseases 2016, 213: 1796-1799. PMID: 26768249, PMCID: PMC4857469, DOI: 10.1093/infdis/jiw014.Peer-Reviewed Original ResearchConceptsMonths of treatmentMycobacterium tuberculosis infectionTuberculosis infectionTreatment responsePoor early treatment responseProspective cohort studyInitiation of treatmentM. tuberculosis infectionRepetitive units-variable numberEarly treatment responsePersistent culture positivityCohort studyClinical managementCulture positivityHigher oddsInfectionTuberculosisPrevalenceTreatmentMonthsResponsePatientsKwaZulu-NatalHost heterogeneityPositivity
2015
How competition governs whether moderate or aggressive treatment minimizes antibiotic resistance
Colijn C, Cohen T. How competition governs whether moderate or aggressive treatment minimizes antibiotic resistance. ELife 2015, 4: e10559. PMID: 26393685, PMCID: PMC4641510, DOI: 10.7554/elife.10559.Peer-Reviewed Original Research
2014
High risk and rapid appearance of multidrug resistance during tuberculosis treatment in Moldova.
Jenkins HE, Crudu V, Soltan V, Ciobanu A, Domente L, Cohen T. High risk and rapid appearance of multidrug resistance during tuberculosis treatment in Moldova. European Respiratory Journal 2014, 43: 1132-41. PMID: 24558181, PMCID: PMC4005038, DOI: 10.1183/09031936.00203613.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisMDR-TB diagnosisMDR-TB casesTB treatmentFirst-line TB drugsAmbulatory TB treatmentMDR-TB riskDrug susceptibility testingNosocomial transmissionInitial diagnosisPercentage of individualsTB drugsTuberculosis treatmentEarly treatmentHigh riskSputum specimensSurveillance databasePrevious incarcerationDrug resistanceMultidrug resistanceDiagnosisTreatmentBaseline resistanceRapid appearanceRisk
2013
Treatment outcome of multi-drug resistant tuberculosis in the United Kingdom: retrospective-prospective cohort study from 2004 to 2007.
Anderson LF, Tamne S, Watson JP, Cohen T, Mitnick C, Brown T, Drobniewski F, Abubakar I. Treatment outcome of multi-drug resistant tuberculosis in the United Kingdom: retrospective-prospective cohort study from 2004 to 2007. Eurosurveillance 2013, 18 PMID: 24128699, DOI: 10.2807/1560-7917.es2013.18.40.20601.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntibiotics, AntitubercularAntitubercular AgentsChildChild, PreschoolDrug Resistance, Multiple, BacterialFemaleFluoroquinolonesHumansInfantInfant, NewbornMaleMicrobial Sensitivity TestsMiddle AgedMycobacterium tuberculosisPatient ComplianceProspective StudiesRetrospective StudiesSurveys and QuestionnairesTreatment OutcomeTuberculosis, Multidrug-ResistantUnited KingdomYoung AdultConceptsMultidrug-resistant tuberculosisTreatment outcomesRetrospective-prospective cohort studyWorld Health Organization targetMulti-drug resistant tuberculosisMDR-TB patientsMDR-TB treatmentMDR-TB casesFurther drug resistanceTreatment completion ratesSuccessful treatment outcomeUnited Kingdom guidelinesIndividualised regimensCohort studyMonths treatmentResistant tuberculosisTreatment completionInfectious casesDrug resistanceDrug sensitivitySuccessful outcomeOrganization targetBacteriostatic drugsOutcomesTreatmentIsoniazid-resistant Tuberculosis in Children
Yuen CM, Tolman AW, Cohen T, Parr JB, Keshavjee S, Becerra MC. Isoniazid-resistant Tuberculosis in Children. The Pediatric Infectious Disease Journal 2013, 32: e217-e226. PMID: 23348808, PMCID: PMC3709006, DOI: 10.1097/inf.0b013e3182865409.Peer-Reviewed Original ResearchConceptsIsoniazid-resistant tuberculosisLatent tuberculosis infectionTuberculosis diseaseTuberculosis infectionIsoniazid resistancePediatric tuberculosis patientsTreatment of childrenIsoniazid-resistant strainsReports of childrenEffective regimensTuberculosis patientsTuberculosis treatmentAppropriate treatmentInclusion criteriaMedian proportionSystematic reviewRifampin resistanceDiseaseTuberculosisRegimensChildrenTreatmentInfectionIsoniazidHigher proportion
2012
Mixed-Strain Mycobacterium tuberculosis Infections and the Implications for Tuberculosis Treatment and Control
Cohen T, van Helden PD, Wilson D, Colijn C, McLaughlin MM, Abubakar I, Warren RM. Mixed-Strain Mycobacterium tuberculosis Infections and the Implications for Tuberculosis Treatment and Control. Clinical Microbiology Reviews 2012, 25: 708-719. PMID: 23034327, PMCID: PMC3485752, DOI: 10.1128/cmr.00021-12.Peer-Reviewed Original ResearchConceptsMixed infectionsTuberculosis infectionM. tuberculosis infectionTuberculosis control strategiesMycobacterium tuberculosis infectionTreatment of patientsMultiple distinct strainsTuberculosis treatmentInfectionMycobacterium tuberculosisEpidemiological importanceDistinct strainsTreatmentNumerous studiesPatientsTuberculosisDiagnosisHighlight challengesIndividualsLinking Surveillance with Action against Drug-Resistant Tuberculosis
Cohen T, Manjourides J, Hedt-Gauthier B. Linking Surveillance with Action against Drug-Resistant Tuberculosis. American Journal Of Respiratory And Critical Care Medicine 2012, 186: 399-401. PMID: 22592806, PMCID: PMC3443807, DOI: 10.1164/rccm.201203-0394pp.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisForms of TBDrug-resistant TBManagement of patientsDrug-resistant tuberculosisSecond-line drugsEffective public health responseDrug susceptibility testingPublic health responseQuality-assured treatmentMDRTB treatmentIncident casesHigh burdenProgrammatic dataHealth responseDrug resistanceSusceptibility testingImproved surveillance methodsPopulation subgroupsSurveillance methodsSurveillance activitiesTuberculosisClear roleTreatmentRecent global estimates
2009
What is the mechanism for persistent coexistence of drug-susceptible and drug-resistant strains of Streptococcus pneumoniae?
Colijn C, Cohen T, Fraser C, Hanage W, Goldstein E, Givon-Lavi N, Dagan R, Lipsitch M. What is the mechanism for persistent coexistence of drug-susceptible and drug-resistant strains of Streptococcus pneumoniae? Journal Of The Royal Society Interface 2009, 7: 905-919. PMID: 19940002, PMCID: PMC2871802, DOI: 10.1098/rsif.2009.0400.Peer-Reviewed Original ResearchConceptsDrug-resistant strainsStreptococcus pneumoniaeInfectious diseasesDrug-susceptible strainsHigher reproduction numberCent prevalenceSubstantial prevalencePersistent coexistenceDrug resistanceMultiple infectionsAntimicrobial useResistant strainsBacterial spreadAntimicrobial resistancePrevalenceDiseasePneumoniaeOutcomesReproduction numberTreatmentHost interactionsPathogensCoinfectionExtensively Drug‐Resistant Tuberculosis and HIV/AIDS
Murray M, Cohen T. Extensively Drug‐Resistant Tuberculosis and HIV/AIDS. 2009, 253-275. DOI: 10.1002/9783527627905.ch10.Peer-Reviewed Original Research